Merck’s weight-loss pill deal: what it means for Eli Lilly
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill (oral) developed by the Chinese drugmaker.
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
Eli Lilly Wants to Join Lawsuit Over Compounded Weight-Loss Drugs
The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it cannot rely on the FDA to protect it's interests.
Should Pharmaceutical Companies Sell Weight-Loss Drugs Directly to Consumers?
Conversely, Eduardo Grunvald, MD, medical director of the weight management program at UC San Diego Health, sees less of an issue as long as there is a legitimate prescriber. Some of his patients have found it easier to get access to tirzepatide during shortages using LillyDirect.
Competition will make weight-loss drugs better, cheaper and bigger
Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy,
Eli Lilly asks to join FDA in opposing lawsuit from pharmacies
CNBC's Becky Quick reports on news from Eli Lilly. Court throws out Biden FCC’s net neutrality rule 20 Incredible Cosplayers Who Nailed Their Characters Perfectly College football fans had jokes after Georgia's Parker Jones got a sideline penalty for colliding with a ref The 14 Things in Your Bathroom You Should Get Rid of Immediately Apple agrees to pay $95 million to settle Siri eavesdropping claims I’m a Retired Boomer: Here Are 6 Things I No Longer Buy Because They’re a Waste of Money Scientists discovered 50,
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some pharmacies have practiced in mass-marketing copies of its highly popular GLP-1 medications.
Lilly seeking to join lawsuit over compounded GLP-1 drugs
Eli Lilly (NYSE:LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that weight-loss and diabetes drugs such as Lilly's (NYSE:LLY) tirzepatide are no longer in short supply.
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...
The Motley Fool23d
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly expects to have data from a late-stage trial involving orforglipron by April. This weight loss pill helped patients lose nearly 15% of their weight in a phase 2 trial. Lilly has ...
Eli Lilly’s Zepbound drug likely to dominate global obesity market: Report
Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...
Daily12d
Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market
Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...